At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SGMT Sagimet Biosciences Inc.
Closed 09-29 16:00:00 EDT
9.33
-0.61
-6.14%
盘后9.33
+0.000.00%
19:50 EDT
High9.92Low9.25Vol860.05K
Open9.92D1 Closing9.94Amplitude6.74%
Mkt Cap579.94MTradable Cap520.43MTotal Shares62.16M
T/O8.07MT/O Rate1.54%Tradable Shares55.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Sagimet Biosciences Schedules Virtual KOL Event on Denifanstat Acne Program
Reuters  ·  09-28 19:04
Sagimet Biosciences Schedules Virtual KOL Event on Denifanstat Acne Program
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)
TIPRANKS  ·  09-28 18:20
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)
Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts
TIPRANKS  ·  09-26
Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts
Sagimet Biosciences Down over 15%, on Pace for Largest Percent Decrease Since April 2025
Dow Jones  ·  09-25
Sagimet Biosciences Down over 15%, on Pace for Largest Percent Decrease Since April 2025
Sagimet Biosciences Price Target Announced at $7.00/Share by Goldman Sachs
Dow Jones  ·  09-24
Sagimet Biosciences Price Target Announced at $7.00/Share by Goldman Sachs
H.C. Wainwright Remains a Buy on Sagimet Biosciences, Inc. Class A (SGMT)
TIPRANKS  ·  09-22
H.C. Wainwright Remains a Buy on Sagimet Biosciences, Inc. Class A (SGMT)
Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8
MT Newswires Live  ·  09-09
Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8
Sagimet Biosciences Initiated at Overweight by Cantor Fitzgerald
Dow Jones  ·  09-09
Sagimet Biosciences Initiated at Overweight by Cantor Fitzgerald
Sagimet Biosciences initiated with an Overweight at Cantor Fitzgerald
TIPRANKS  ·  09-09
Sagimet Biosciences initiated with an Overweight at Cantor Fitzgerald
Sagimet Biosciences Inc. : Barclays Raises to Overweight from Equal-Weight; Raises Target Price to $18 from $8
THOMSON REUTERS  ·  09-09
Sagimet Biosciences Inc. : Barclays Raises to Overweight from Equal-Weight; Raises Target Price to $18 from $8
Sagimet Biosciences to Present at Cantor Global Healthcare Conference
Reuters  ·  09-02
Sagimet Biosciences to Present at Cantor Global Healthcare Conference
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
GlobeNewswire  ·  09-02
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.
Dow Jones  ·  08-25
Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.
Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained
TIPRANKS  ·  08-25
Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained
Sagimet Biosciences advances AURORA clinical trial
TIPRANKS  ·  08-25
Sagimet Biosciences advances AURORA clinical trial
Sagimet Advances Aurora Phase 3 Acne Trial of Denifanstat, Targets Q4 2026 Enrollment
Reuters  ·  08-25
Sagimet Advances Aurora Phase 3 Acne Trial of Denifanstat, Targets Q4 2026 Enrollment
Sagimet Biosciences Advances Aurora U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
THOMSON REUTERS  ·  08-25
Sagimet Biosciences Advances Aurora U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
Sagimet Biosciences - Patient Screening for Aurora Phase 3 Trial to Begin in October 2026
THOMSON REUTERS  ·  08-25
Sagimet Biosciences - Patient Screening for Aurora Phase 3 Trial to Begin in October 2026
Sagimet Biosciences Inc.: Anticipate Submitting an Nda upon Completion of 12-Week Phase of Study
THOMSON REUTERS  ·  08-25
Sagimet Biosciences Inc.: Anticipate Submitting an Nda upon Completion of 12-Week Phase of Study
Sagimet Biosciences - All Clinical Trial Sites Identified and Cro Retained for Aurora Phase 3 Trial
THOMSON REUTERS  ·  08-25
Sagimet Biosciences - All Clinical Trial Sites Identified and Cro Retained for Aurora Phase 3 Trial

Introduction

Company Name.
Sagimet Biosciences Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Issue price:
--